Form Approved OMB No. 0990-Exp. Date XX/XX/20XX



THE NATIONAL TISSUE RECOVERY THROUGH UTILIZATION SURVEY

SECTION 4 - Tissue Processing

The Office of the Assistant Secretary for Health, Department of Health and Human Services (HHS), through a contract with the American Association of Tissue Banks, is conducting the 2016 National Tissue Recovery through Utilization Survey (NTRUS).

ххххх

Your responses will remain anonymous in the final dataset. While results of this survey will be released in aggregate form and data may be made available in the form of a de-identified dataset, no specific institutional identifiable information will be included.

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0990-xxxx. The time required to complete this information collection is estimated to average 60 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: U.S. Department of Health & Human Services, OS/OCIO/PRA, 200 Independence Ave., S.W., Suite 336-E, Washington D.C. 20201, Attention: PRA Reports Clearance Officer

Tissue Processing

The survey provides definitions for specific donors and tissue types. To facilitate accurate totals, provide counts using the descriptions provided. Where terms are *italicized*, use the definitions found at AATB Standard A2.000 DEFINITIONS OF TERMS. Some terms and/or definitions are new and some have been revised. Refer to the NTRUS Definitions of Terms document provided with this survey.

The information you are reporting is for the following physical locations(s) by name, city and state:

- A. name, city, state
- B. name, city, state

(need capability for multiple lines/entries)

Which of the following types of tissue did your tissue bank process? (Check all that apply)

TISSUE FROM DECEASED DONORS

□ musculoskeletal (i.e., bone, cartilage, osteochondral grafts, osteoarticular grafts)

□ soft tissue (i.e., fascia lata, ligaments, tendons, pericardium, nerves, peritoneal membrane, adipose)

- □ cardiac tissue
- □ vascular tissue
- 🗆 skin
- 🗆 cellular tissue
- 🗆 dura mater

□ other *tissue* from deceased donors (specify) _____

How many total deceased donors did your *tissue bank process*? (**count one donor only once**)

What is the average graft yield (#) per deceased donor (for all tissue types combined)? _____

Note: Graft yield is defined as the total number of *finished tissue* grafts *processed* from one donor.

TISSUE FROM LIVING DONORS

□ living donor tissue (i.e., birth tissue, surgical bone, skin for allogeneic use, or autologous bone)

other tissue from living donors (specify) _____

How many total living donors did your tissue bank process? (count one donor only once)

What is the average graft yield (#) per living donor (for all tissue types combined)? _____

Note: Graft yield is defined as the total number of finished tissue grafts processed from one donor.

How many total donors of the following types of *tissues* did your *tissue bank process*:

TISSUE FROM DECEASED DONORS

musculoskeletal

bone _____

cartilage (e.g., costal, articular)

osteochondral grafts – **fresh/refrigerated** _____ (i.e., an *allograft* consisting of a section, condyle, or plug of bone with an intact articular surface)

osteochondral grafts - **frozen/cryopreserved** _____ (i.e., an a*llograft* consisting of a section, condyle, or plug of bone with an intact articular surface)

osteoarticular grafts – **fresh/refrigerated** _____(i.e., a large weight bearing *allograft* with intact articular surfaces consisting of a joint with associated soft tissue and bone)

osteoarticular grafts - **frozen/cryopreserved** _____ (i.e., a large weight bearing *allograft* with intact articular surfaces consisting of a joint with associated soft tissue and bone)

<u>soft tissue</u>

fascia lata _____

ligaments (i.e., patellar) _____

tendons (e.g., Achilles, gracillis, anterior/posterior tibialis, semitendinosus, flexors/extensors, peroneus longus) ____

rotator cuff _____

pericardium _____

nerves _____

peritoneal membrane____

adipose _____

cardiac tissue

valved conduits _____

non-valved conduits _____

patch graft_____

aortoiliac graft _____

vascular tissue
arteries
vein grafts
<u>skin</u>
thin
thick
full-thickness
cellular tissue
<u>dura mater</u>
tissue as a device
(i.e., products and combination products requiring PMA or 510k clearance; regulated under the FD&C Act as well as under 21 CFR Part 1271 from Section 361 of the PHSA)
tissue as a biological product
(i.e., products requiring BLA or IND; regulated under Section 351 of the PHSA and/or the FD&C Act, as well as under 21 CFR Part 1271 from Section 361 of the PHSA)
tissue as a drug
(i.e., products requiring IND/NDA; regulated under Section 201 of the FD&C Act, as well as under 21 CFR 1271 from Section 361 of the PHSA)
other <i>tissue</i> from deceased donors (specify); indicate number for each

How many donors of the following types of tissues did your tissue bank process:

TISSUE FROM LIVING DONORS

birth tissue

amniotic membrane (only)_____ chorionic membrane (only) _____ amniotic + chorionic membrane _____ amniotic fluid _____ Wharton's jelly _____ placental/chorionic disc _____ umbilical cord tissue _____ umbilical vein _____ other *birth tissue* (specify)_____; indicate number for each _____

surgical bone

skin for allogeneic use

autologous bone _____

autologous parathyroid

tissue as a device _____

(i.e., products and combination products requiring PMA or 510k clearance; regulated under the FD&C Act as well as under 21 CFR Part 1271 from Section 361 of the PHSA)

tissue as a biological product

(i.e., products requiring BLA or IND; regulated under Section 351 of the PHSA and/or the FD&C Act, as well as under 21 CFR Part 1271 from Section 361 of the PHSA)

tissue as a drug _____

(i.e., products requiring IND/NDA; regulated under Section 201 of the FD&C Act, as well as under 21 CFR 1271 from Section 361 of the PHSA)

other tissue from living donors (specify) _____; indicate number for each _____

How does your *tissue bank* treat *tissues* with radiation PRIOR to *processing* (*non-terminal irradiation*)? Check all that apply.

□ we do not treat *tissues* with radiation prior to *processing*

□ electron beam radiation only; indicate dose: _____

□ gamma radiation only, below 1.5 Mrads (15 kGy)

□ gamma radiation only, 1.5 - 2.5 Mrads (15-25 kGy)

□ gamma radiation only, above 2.5 Mrads (25 kGy)

How does your *tissue bank* treat tissues with radiation to reduce/eliminate microorganisms as a FINAL treatment (terminal irradiation)? Check all that apply.

□ we do not treat *tissues* with radiation as a final treatment

□ electron beam radiation only; indicate dose: _____

□ gamma radiation only, below 1.5 Mrads (15 kGy)

□ gamma radiation only, 1.5 - 2.5 Mrads (15-25 kGy)

□ gamma radiation only, above 2.5 Mrads (25 kGy)

Indicate how many musculoskeletal <u>GRAFTS</u> were *processed* using the following methods (if none, enter zero):

electron beam radiation (only)_____

gamma radiation (only)_____

ethylene oxide (only) _____

antibiotics (only) _____

Types of proprietary/patented processing (only)

Allowash® _____

ATP _____

BioCleanse [®] Process _____

Clearant Process[®]

Tutoplast[®] Process____

NovaSterilis (supercritical CO2)

Other proprietary methods (specify) _____; indicate number _____

Combinations of Antibiotics and Radiation - Musculoskeletal

For each combination used specify antibiotic(s), radiation target dose (below 1.5 Mrads, between 1.5 and 2.5 Mrads, and above 2.5 Mrads) and number of grafts *processed* using these combination methods

Antibiotic(s) (specify) Radiation Target Dose # grafts

Combinations of Proprietary/Patented Processing then Radiation - Musculoskeletal

For each combination used please specify proprietary *processing* method, radiation target dose (below 1.5 Mrads, between 1.5 and 2.5 Mrads, and above 2.5 Mrads) and number of grafts *processed* using these combination methods

Proprietary/Patented Method (specify) Radiation Target Dose # grafts

Report any other combinations of methods used: _____

Indicate how many soft tissue <u>GRAFTS</u> (i.e., fascia lata, ligaments, tendons, pericardium, nerves, peritoneal membrane, adipose) were *processed* using the following methods (if none, enter zero):

electron beam radiation (only) _____

gamma radiation (only)_____

ethylene oxide (only) _____

antibiotics (only) _____

Types of Proprietary/Patented Processing (only)

Allowash[®]

ATP _____

BioCleanse [®] Process _____

Clearant Process[®]

Tutoplast[®] Process_____

NovaSterilis (supercritical CO2)	
----------------------------------	--

other proprietary methods (specify) _____; indicate number _____

Combinations of Antibiotics and Radiation - Soft Tissue Grafts

For each combination used please specify antibiotic(s), radiation target dose (below 1.5 Mrads, between 1.5 and 2.5 Mrads, and above 2.5 Mrads) and number of grafts processed using these combination methods

Antibiotic(s) (specify) Radiation Target Dose # grafts

Combinations of Proprietary/Patented Processing then Radiation - Soft Tissue Grafts

For each combination used please specify proprietary *processing* method, radiation target dose (below 1.5 Mrads, between 1.5 and 2.5 Mrads, and above 2.5 Mrads) and number of grafts *processed* using these combination methods

Proprietary/Patented Method (specify) Radiation Target Dose # grafts

Report any other combinations of methods used:

Indicate how many *cardiac tissue* <u>GRAFTS</u> were preserved using the following methods (if none, enter zero):

refrigerated only (i.e., provided for use as fresh) _____

controlled-rate electronic programmable freezing _____

other methods (specify) _____; indicate number _____

Indicate how many units of *cardiac tissue* <u>GRAFTS</u> were *processed* into *finished tissue* for each of the following types (enter 0 if not applicable):

acellular/decellularized: _____

NOT acellular/decellularized: _____

other type (specify); indicate number
Indicate how many vascular tissue <u>GRAFTS</u> were preserved using the following methods (if none, enter zero):
refrigerated only (i.e., provided for use as fresh)
controlled-rate electronic programmable freezing
other methods (specify); indicate number
Indicate how many units of <i>vascular tissue <u>GRAFTS</u> were processed</i> into <i>finished tissue</i> for each of the following types (enter 0 if not applicable):
acellular/decellularized:
NOT acellular/decellularized:
other type (specify); indicate number
Indicate how many <i>skin <u>GRAFTS</u> were processed using the following methods (if none, enter zero):</i>
electron beam radiation (only)
gamma radiation (only)
ethylene oxide (only)
antibiotics (only)
Types of Proprietary/Patented Processing (only)
Allowash [®]
ATP
BioCleanse [®] Process
Clearant Process®
Tutoplast [®] Process
NovaSterilis (supercritical CO2)
other proprietary methods (specify); indicate number
Combinations of Antibiotics and Radiation – Skin
For each combination used please specify antibiotic(s), radiation target dose (below 1.5 Mrads, between 1.5 and 2.5 Mrads, and above 2.5 Mrads) and number of grafts <i>processed</i> using these combination methods
Antibiotic(s) (specify) Radiation Target Dose # grafts

Combinations of Proprietary/Patentec	Processing then Radiation –	Skin	
For each combination used please spe Mrads, between 1.5 and 2.5 Mrads, ar combination methods		nethod, radiation target dose (below 1.5 nber of grafts <i>processed</i> using these	
Proprietary/Patented Method (specify) Radiation Target Dose	# grafts	
Report any other combinations of met	nods used:		
Indicate how many birth tissue <u>GRAF</u>	<u>FS</u> were <i>processed</i> using the f	following methods (if none, enter zero):	
electron beam radiation (only)			
gamma radiation (only)			
ethylene oxide (only)			
antibiotics (only)			
filtration (only)			
ultraviolet light (only)			
Types of Proprietary/Patented Process	sing (only)		
Allowash [®]			
ATP			
BioCleanse [®] Process			
Clearant Process [®]			
Tutoplast [®] Process			
NovaSterilis (supercritical CO2)		

Purion [®] Process			
Cryotek™ Process			
other proprietary methods (specify); indicate number for each			
Combinations of Antibiotics and Radiation – Birth Tissue Grafts			
For each combination used please specify antibiotic(s), radiation target dose (below 1.5 Mrads, between 1.5 and			
2.5 Mrads, and above 2.5 Mrads) and number of grafts <i>processed</i> using these combination methods			
Antibiotic(s) (specify)Radiation Target Dose# grafts			
<u>Combinations of Proprietary/Patented Processing then Radiation – Birth Tissue Grafts</u>			
For each combination used please specify proprietary <i>processing</i> method, radiation target dose (below 1.5			
Mrads, between 1.5 and 2.5 Mrads, and above 2.5 Mrads) and number of grafts <i>processed</i> using these combination methods			
Proprietary/Patented Method (specify) Radiation Target Dose # grafts			
· · · · ·			
Report any other combinations of methods used:			
For what applications does your <i>tissue bank</i> process demineralized bone (check all that apply)?			
□ we do not process demineralized bone			
□ orthopedic surgery			
🗆 dental/periodontal procedures			
□ neurosurgery			
other applications (specify)			
Does your tissue bank process skin for use as fresh grafts (not cryopreserved)?			
, , , , , , , , , , , , , , , , , , , ,			

□ no, we do not <i>process skin</i>			
□ no, we <i>process skin</i> , but not for use as fresh grafts			
□ yes, we <i>process skin</i> for use as fresh grafts			
Indicate how much <i>skin</i> (in square feet) was preserved by each of the following methods (enter 0 if not applicable)			
refrigerated only			
controlled-rate electronic programmable freezing			
heat sink freezing method			
lyophilized			
dehydrated			
dessicated			
other methods (specify); indicate number			
Indicate how much <i>skin</i> (in square feet) was processed into <i>finished tissue</i> for each of the following types (enter 0 if not applicable):			
acellular/decellularized:			
NOT acellular/decellularized:			
Indicate how many units of <i>birth tissue</i> were preserved using the following methods; this refers to the preservation method used only for <i>finished tissue</i> (enter 0 if not applicable)			
refrigerated only (i.e., provided for use as fresh)			
simple freezing			
controlled-rate electronic programmable freezing			
lyophilized			
dehydrated			
dessicated			
other methods (specify); indicate number			
Indicate how many units of <i>birth tissue</i> were <i>processed</i> into <i>finished tissue</i> for each of the following types (enter 0 if not applicable):			
acellular/decellularized:			

NOT acellular/decellularized: _____

For w	hat applications does your tissue bank process birth tissue (check all that apply)?
	□ we do not process birth tissue
	□ ophthalmic
	□ leg/foot ulcers
	□ orthopedic
	🗆 dental/periodontal
	neurosurgical and spine
	🗆 burns
	🗆 general surgical
	🗆 other general uses (specify)
Indica	ate how many donors of <i>skin</i> were <i>recovered</i> by the following:
	AATB-accredited OPOs/tissue banks
	non-AATB accredited OPOs/tissue banks
	health care facilities (e.g., hospital or surgical center)
Indica	ate how many donors of musculoskeletal tissue were <i>recovered</i> by the following:
	AATB-accredited OPOs/tissue banks
	non-AATB accredited OPOs/tissue banks
	health care facilities (e.g., hospital or surgical center)
Indica	ate how many donors of soft tissue were <i>recovered</i> by the following:
	AATB-accredited OPOs/tissue banks
	non-AATB accredited OPOs/tissue banks
	health care facilities (e.g., hospital or surgical center)

dicate hov	v many donors of cardiac tissue or vascular tissue were recovered by the following:
cardiac tiss	le
AAT	B-accredited OPOs/tissue banks
non	AATB accredited OPOs/tissue banks
heal	th care facilities (e.g., hospital or surgical center)
vascular tis	sue
AAT	B-accredited OPOs/tissue banks
non	AATB accredited OPOs/tissue banks
heal	th care facilities (e.g., hospital or surgical center)
ndicate hov	v many donors of <i>birth tissue</i> were provided by the following:
hos	oital delivery/birth centers
free	standing birth centers (not at a hospital)
AAT	B-accredited OPOs/tissue banks
non	AATB accredited OPOs/tissue banks
othe	r (specify)
ndicate hov	v many donors of <i>birth tissue</i> delivered by:
esarean se	ction
/aginally	
I Check her	e if your <i>tissue bank</i> sent any human <i>tissue</i> to another <i>tissue bank</i> for further manufacture.
Nhat tissue	was sent for further manufacture? Check all that apply:
□ de	mineralized bone matrix
□ ca	ncellous bone

other (specify)

□ Check here if your *tissue bank processed* any human tissue from non-U.S. sources

List the non-U.S. countries: _____

□ Check here if your *tissue bank* imported human tissue from other countries for *processing* and *distribution* in the U.S.

List the countries from which donors were imported, the number of donors *processed*, the general types of tissue grafts, and the quantities *distributed*

Country of Origin No. of donors processed Types of tissue grafts Quantity of grafts distributed

(multiple lines)

□ Check here if your *tissue bank processed tissue* from other countries only for *distribution* by countries other than the U.S. (i.e., *processing* contract only)

Indicate the tissue received and the country of origin:

TISSUE FROM DECEASED DONORS

□ musculoskeletal (i.e., bone, cartilage, osteochondral grafts, osteoarticular grafts):

□ soft tissue (i.e., fascia lata, ligaments, tendons, pericardium, nerves, peritoneal membrane, adipose):

🗆 dura mater	
--------------	--

\Box cardiac	tissue	
----------------	--------	--

🗆 vascular tissue _____

🗆 skin _____

TISSUE FROM LIVING DONORS

□ surgical bone _____

□ skin for allogeneic use _____

🗆 autologous bone _____

🗆 birth tissue_____

_